Sarepta's ELEVIDYS Shows Positive Results in Older Duchenne Muscular Dystrophy Patients

Sarepta Therapeutics presented new data indicating that ELEVIDYS (delandistrogene moxeparvovec) provides clinically meaningful functional benefits and sustained treatment effects for older ambulatory Duchenne muscular dystrophy patients aged 8-12 years. The findings, shared at the 2026 World Muscle Society Annual Congress, also confirmed a safety profile consistent with prior observations. This expands the potential patient population for this gene therapy.